Abstract C031: Targeting granulocytic MDSC-derived inflammasome activation to overcome stromal inflammation in pancreatic cancer
Authors: Nilesh Deshpande, Anna Bianchi, Iago De Castro Silva, Vanessa Garrido, Siddharth Mehra, Samara Singh, Ifeanyichukwu Ogobuiro, Nagaraj Nagathihalli, Nipun B. Merchant, Jashodeep Datta
Journal: Cancer Research (2022)

Abstract Objective: The major drivers of therapeutic resistance in pancreatic ductal adenocarcinoma (PDAC) are myeloid cell-derived signaling that sustains immune tolerance/exclusion, and interleukin-1 (IL-1)-mediated inflammatory polarization of cancer-associated fibroblasts (iCAF) which promotes stromal inflammation by elaborating soluble factors (i.e., CXCL1, IL-6) that further accelerate myeloid chemotaxis. Moreover, we have recently shown that enrichment of pathways related to inflammasome activation-which involves recruitment of ASC complexes culminating in IL-1β generation—is a major contributor to chemoresistance in advanced PDAC patients. However, how these disparate pathways converge to mediate stromal inflammation in PDAC is incompletely understood. Methods: Single-cell RNA sequencing (scRNAseq) and caspase-1 luminescence assays in human and genetically engineered mouse (GEM) PDAC models were interrogated to identify cellular source of inflammasome-derived IL-1β. Gene set enrichment analysis in bulk RNA-sequencing data and signal transduction studies examined novel pathways associated with inflammasome activation in granulocytic myeloid-derived suppressor cells (gMDSC). scRNAseq and ASC-speck formation via confocal microscopy in intratumoral gMDSCs was performed in PKT mice treated with a novel anti-ASC antibody. Results: scRNAseq in human and GEM PDAC models revealed gMDSCs as the dominant source of inflammasome activation-derived IL1B expression. Functionally, caspase-1 activation and ASC-speck formation was strongest in intratumoral gMDSCs, compared with tumor-cell, CAF, macrophage, T-cell, and dendritic cell, compartments. Investigating developmental trajectories of single-cell transcriptomes in intratumoral gMDSCs from Panc02 tumors revealed an activated Cd14+ gMDSC state with strong co-expression of Cxcr2 and Il1b. As such, treatment of PKT GEM and orthotopically injected KPC tumor-bearing mice with CXCR2 inhibitor AZD5069 significantly abrogated inflammasome activation in intratumoral and splenic gMDSCs. In vitro signal transduction and RNA-seq studies revealed cooperativity between Tlr4-Myd88 and Cxcr2-Tpl2-p38 signaling in activating gMDSC-restricted inflammasome signaling. Co-culture of intratumoral gMDSCs and KPC CAFs ex vivo revealed strong induction of CAF-intrinsic Il6/Cxcl1 expression, which was dependent in part on CAF-Il1r1 expression and inflammasome activation in gMDSCs. We next used antibody to target ASC-a common downstream adaptor complex inducing inflammasomes-in vivo. Treatment of PKT mice with this anti-ASC antibody significantly attenuated ASC-speck formation in intratumoral gMDSCs as well as CAF-specific Il6/Cxcl1 expression via scRNAseq. Conclusions: These data uncover granulocytic MDSCs as the dominant source of inflammasome activation derived-IL1β in the PDAC TME, which promotes stromal inflammation via iCAF polarization. Therapeutic approaches-such as anti-ASC treatment-targeting gMDSC-intrinsic inflammasome activation may mitigate stromal inflammation and overcome therapeutic resistance in PDAC. Citation Format: Nilesh Deshpande, Anna Bianchi, Iago De Castro Silva, Vanessa Garrido, Siddharth Mehra, Samara Singh, Ifeanyichukwu Ogobuiro, Nagaraj Nagathihalli, Nipun B. Merchant, Jashodeep Datta. Targeting granulocytic MDSC-derived inflammasome activation to overcome stromal inflammation in pancreatic cancer [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr C031.